GSK's Fair Value Estimate Edges Higher Amid Mixed Analyst Sentiment
ByAinvest
Thursday, Feb 5, 2026 9:39 pm ET1min read
GSK--
GSK's fair value estimate has been raised to £18.83 from £18.73, with some analysts increasing price targets despite caution around the company's pipeline and execution. JPMorgan raised its target to 1,500 GBp from 1,400 GBp while staying cautious, while Barclays downgraded GSK to Underweight from Equal Weight, highlighting limited upcoming pipeline readouts and the new CEO's limited room to maneuver. Analysts see mixed signals, with some supporting the current valuation while others flag execution risk and limited upcoming readouts.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet